Continuous Glucose Monitoring for Women With Diabetes Mellitus in the Intrapartum and Postpartum Inpatient Care

Ohio State University40 enrolled

Overview

Diabetes mellitus affects roughly 8% of pregnancies and is associated with significant perinatal and maternal morbidity. Increasing numbers of women are either entering pregnancy with a continuous glucose monitor (CGM) or are initiating use during pregnancy, with data emerging suggesting improved outcomes among those using CGM. Since the introduction of CGM in the late 1990s, there has been slow acceptance of their validation and use in the inpatient setting. The investigators propose an observational prospective cohort study to analyze the correlation of CGM data with traditional capillary glucose readings in the intrapartum and postpartum settings.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes, Gestational

Interventions

Dexcom G6DEVICE

Continuous glucose monitoring

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-50 years * Women with a viable singleton or twin intrauterine pregnancy between 22 5/7 and 41 6/7 weeks gestation based on the best obstetric estimate by ACOG criteria * Diagnosis of insulin-dependent pregestational diabetes mellitus (type 1 or type 2 diabetes) * Planning to deliver at OSU Wexner Medical Center * Able to understand the study, and having understood, provide written informed consent in English Exclusion Criteria: * Gestational diabetes mellitus, Maturity Onset Diabetes of Young, and Cystic Fibrosis Related Diabetes * Abnormal obstetrical ultrasound suspicious for major congenital abnormality * Known or suspected fetal aneuploidy (by either CVS, amniocentesis, or cell-free DNA) * Participation in another trial that may influence the primary outcome, without prior approval * Participation in this trial in a prior pregnancy * Higher order pregnancy * History of severe skin allergy to adhesive products or CGM within the previous 3 months

Outcomes

Primary Outcomes

Maternal outcome

Assessed by analyzing the number of hypoglycemic and hyperglycemic episodes prior to and post-delivery as determined by glucose measurements

Time frame: 9 months

Secondary Outcomes

Neonatal outcomes

Assessed by requirement of neonatal antidiabetic care measured in the number of hypoglycemic episode requiring IV dextrose treatment

Time frame: 10 days